|
|
OSUCCC
 |
James P. Thomas, M.D., Ph.D.
Assoc Professor
College of Medicine
Internal Medicine - Hematology/Oncology
6-016 Batelle
1375 Perry Street Columbus,OH. 43201
|
Programs
|
 |
|
|
Current Publications
|
|
Cancer Chemother Pharmacol in press: , 2009
|
|
A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies.
|
|
Bekaii-saab TS, Hill M, Campbell A, Kosuri K, Thomas JP, Villalona MA
|
|
|
Invest New Drugs 27(5): 461-8, 2009
|
|
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
|
|
Mulkerin D, Loconte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G
|
|
|
Oncology 76(5): 333-7, 2009
|
|
Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
|
|
Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS
|
|
|
Cancer Chemother Pharmacol 63(1): 109-15, 2008
|
|
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
|
|
Loconte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J
|
|
|
Invest New Drugs 26(3): 241-7, 2008
|
|
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
|
|
Chan E, Muklerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J
|
|
|
Cancer Chemother Pharmacol 62(4): 727-33, 2008
|
|
A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.
|
|
Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G
|
|
|
JAMA 299(21): 2515-23, 2008
|
|
Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
|
|
Chan JA,, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS
|
|
|
Clin Adv Hematol Oncol 6(1): 44-54, 2008
|
|
Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
|
|
Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S
|
|
|
J Clin Oncol 26(25): 4109-15, 2008
|
|
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
|
|
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson h, Whittom R, Hantel A, Thomas j, Fuchs CS, CALGB 89803
|
|
|
